Global Osteoarthritis Therapeutics Market

Osteoarthritis Therapeutics Market Size, Share, Growth Analysis, By Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), By Drug Type (Viscosupplementation Agents, Non-Steroidal Anti-inflammatory Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region -Industry Forecast 2025-2032

Report ID: SQMIG30K2057 | Region: Global | Published Date: December, 2024
Pages: 166 | Tables: 92 | Figures: 71

Osteoarthritis Therapeutics Market News

  • In November 2024, AbbVie made known the launching of a new injectable biologic medicine to treat knee osteoarthritis so that patients could gain pain relief and improved joint function for longer periods of time. The therapy will be given to the public due to the efficacy shown in recent clinical trials that will replace the traditional surgical methods into less invasive interventions that will benefit patients.
  • In October 2024, Johnson & Johnson unveiled a new advanced viscosupplementation agent aimed at treating knee osteoarthritis. This product is designed to offer superior lubrication and reduce inflammation, offering patients an alternative to oral medications. The company’s strategic R&D investment aims to expand its portfolio of non-surgical osteoarthritis therapies.
  • In September 2024, the next generation of NSAID remedy in osteoarthritis development by Merck & Co. has substantially advanced. It aims at pain reduction with a significant decrease in the gastrointestinal side effects, which is one of the limitations of all present-day therapies. Merck shall further strengthen its position in the OA therapeutics market with this product.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Osteoarthritis Therapeutics Market size was valued at USD 7.99 Billion in 2022 poised to grow from USD 8.54 Billion in 2023 to USD 14.56 Billion by 2031, growing at a CAGR of 6.89% in the forecast period (2024-2031).

The global osteoarthritis therapeutics market is highly competitive, with numerous pharmaceutical companies and biopharmaceutical firms driving innovation. The important players in this sector include Johnson and Johnson, Pfizer, Sanofi, AbbVie, and Merck with their offering of different treatment options like the NSAIDs, biologics, and viscosupplementation agents. The companies are now focusing on research and development, also diversifying products and improving treatment efficiencies to brace themselves for future competition in the market. Partnerships and acquisitions also aid in bolstering the market presence for developing next-generation therapies for osteoarthritis management. 'Johnson & Johnson (USA)', 'Pfizer (USA)', 'Sanofi (France)', 'AbbVie (USA)', 'Merck & Co. (USA)', 'GlaxoSmithKline (United Kingdom)', 'Novartis (Switzerland)', 'Amgen (USA)', 'Bristol-Myers Squibb (USA)', 'Eli Lilly and Co. (USA)', 'Horizon Therapeutics (Ireland)', 'Stryker Corporation (USA)', 'Zimmer Biomet (USA)', 'Mylan Pharmaceuticals (USA)', 'Regeneron Pharmaceuticals (USA)'

The global osteoarthritis therapeutic market promises great potential in the rapidly aging population, especially in developed parts of the world such as North America and Europe. Since older people tend to suffer joint degenerative diseases, an increased number of older individuals translates directly into higher demand for treatments, ultimately driving market expansion and therapeutic innovation.

Rising Adoption of Minimally Invasive Treatments: The shift towards minimal invasive therapies like viscosupplementation and biologic injections, are some of the latest global osteoarthritis therapeutics market trends. These very effective pain relievers as well as joint functional improvements are accompanied with less recovery time than surgeries. Thus, they are becoming more and more popular in the eyes of patients and healthcare providers.

North America dominates the global osteoarthritis therapeutics market due to a combination of factors including a large aging population, high prevalence of osteoarthritis, and advanced healthcare infrastructure. Indeed, the region is said to receive massive healthcare spending, making most available treatment options such as biologics, NSAIDs, and viscosupplementation agents accessible. North America has also been the leading researcher and developer in the space of innovations in therapeutic solutions. Other factors such as government support for improvement in healthcare, along with increasing public awareness of osteoarthritis management, are essential in making the region inherently superior. This, combined with very developed healthcare systems, has given North America dominance over the global osteoarthritis therapeutics market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Laboratory Filtration Market
Buy Now GET FREE SAMPLE
Candle Market
Buy Now GET FREE SAMPLE
Liquid Detergent Market
Buy Now GET FREE SAMPLE
Household Care Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Osteoarthritis Therapeutics Market

Report ID: SQMIG30K2057

$5,300
BUY NOW GET FREE SAMPLE